BIOVICA INTERNATIONAL AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.766 SEK | -7.05% |
|
-25.33% | -31.55% |
| Apr. 13 | Certain B Shares of Biovica International AB are subject to a Lock-Up Agreement Ending on 13-APR-2024. | CI |
| Apr. 12 | Biovica International AB Announces Divitum® Tka in Observational Trial | CI |
| Sales 2024 * | 10M 921K | Sales 2025 * | 116M 10.68M | Capitalization | 160M 14.71M |
|---|---|---|---|---|---|
| Net income 2024 * | -110M -10.13M | Net income 2025 * | -51M -4.7M | EV / Sales 2024 * | 7.3 x |
| Net cash position 2024 * | 86.7M 7.98M | Net cash position 2025 * | 43.01M 3.96M | EV / Sales 2025 * | 1.01 x |
| P/E ratio 2024 * |
-0.15
x | P/E ratio 2025 * |
-0.64
x | Employees | 37 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.54% |
More Fundamentals
* Assessed data
More news
Latest transcript on Biovica International AB
More press releases
| 1 day | -7.05% | ||
| 1 week | -25.33% | ||
| Current month | -28.21% | ||
| 1 month | -30.20% | ||
| 3 months | -30.34% | ||
| 6 months | -36.01% | ||
| Current year | -31.55% |
1 week
1.50
2.49
1 month
1.502.75
Current year
1.503.40
1 year
1.5010.36
3 years
1.5069.00
5 years
1.5069.00
10 years
1.5069.00
| Managers | Title | Age | Since |
|---|---|---|---|
Anders Rylander
CEO | Chief Executive Officer | 54 | 09-12-31 |
Anders Morén
DFI | Director of Finance/CFO | 59 | 22-12-31 |
Hanna Ritzen
CTO | Chief Tech/Sci/R&D Officer | 45 | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 64 | 19-03-19 | |
Annika Berg
BRD | Director/Board Member | 61 | 19-12-31 |
Maria Holmlund
BRD | Director/Board Member | 68 | 15-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 1.766 | -7.05% | 925 286 |
| 24-04-23 | 1.9 | -7.77% | 464,098 |
| 24-04-22 | 2.06 | -6.79% | 302,655 |
| 24-04-19 | 2.21 | -3.91% | 95,115 |
| 24-04-18 | 2.3 | -2.75% | 150,954 |
Delayed Quote Nasdaq Stockholm, April 24, 2024 at 05:01 am EDT
More quotes
Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.
Calendar
2024-06-17
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.9
SEK
Average target price
15
SEK
Spread / Average Target
+689.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -31.55% | 14.75M | |
| -14.13% | 11.53B | |
| +45.76% | 3.31B | |
| -35.86% | 2.11B | |
| -18.27% | 2.05B | |
| -27.92% | 1.49B | |
| +18.02% | 1.02B | |
| -3.49% | 741M | |
| -31.42% | 426M | |
| +26.64% | 372M |
- Stock Market
- Equities
- BIOVIC B Stock
